BRAF and neoplasm: The Hippo pathway effector YAP (encoded by YAP1) was identified through a genetic screen in BRAF-mutant tumor cells as an alternative survival mechanism contributing to resistance to anti-RAF and anti-MEK therapy [84]; increased expression of YAP was a biomarker of worse initial response to RAF and MEK inhibition in patients in tumors harboring BRAF V600E mutations [84].